Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial.
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback